Nasal peptides can reach the brain via two narrow neural pathways

How do nasal peptides reach the brain?

Nasal peptides can reach the central nervous system by two documented routes that bypass the blood-brain barrier: the olfactory pathway and the trigeminal pathway. The olfactory pathway runs along olfactory sensory neurons, whose endings sit in a small patch of epithelium high in the nasal cavity and whose axons project directly into the olfactory bulb. The trigeminal pathway runs along branches of the trigeminal nerve that innervate the rest of the nasal mucosa and enter the brainstem.

Reviews describe both routes consistently. Intranasal delivery can circumvent the blood-brain barrier "due to the special anatomy of the olfactory and trigeminal neural pathways that connect the nasal mucosa with the brain and the perivascular pathway within the CNS" ^[4]. Other reviews frame the same anatomy as a way to achieve "higher cerebrospinal fluid drug bioavailability compared to intravenous routes" for select molecules ^[6]⁠^[7].

Why doesn't most of a nasal peptide dose reach the brain?

Most of a nasal spray lands on ordinary respiratory tissue that drains toward the throat and general circulation, not toward neurons, because the olfactory epithelium is a small fraction of the nasal surface. A pathway existing is not the same as a pathway being efficient. Only the olfactory epithelium connects directly to the olfactory bulb.

Three technical obstacles shrink the dose further. Mucociliary clearance sweeps material out of the nose within minutes, nasal enzymes degrade unprotected peptides, and only a small mucosal surface connects to neural tissue ^[3]⁠^[7].

Device and formulation therefore matter, although none of the studies cited below supplies a human device-effect number. Reviews of intranasal engineering describe nanoparticle carriers, mucoadhesive formulations and delivery devices built to keep more of a dose in contact with olfactory tissue for longer, because without those modifications, clearance and swallowing dominate ^[3]⁠^[5]⁠^[6].

The mechanism reviews behind nose-to-brain claims draw largely on preclinical work, nanoparticle engineering and in vitro barrier models, not on measurements in unanesthetized people using a spray bottle at home ^[3]⁠^[5]⁠^[8]. That distinction matters more than almost anything else in nasal peptide delivery. The reviews explain why researchers are optimistic about the route and catalogue its obstacles ^[3]⁠^[5]⁠^[6]⁠^[7]⁠^[8].

Has nose-to-brain delivery been measured in living humans?

Yes, for oxytocin: a randomized study gave healthy adults intranasal oxytocin or placebo and found oxytocin rose significantly in both plasma and cerebrospinal fluid ^[1]. The study sampled blood and CSF over time, and its result is real, useful evidence that the nose-to-brain route can function in humans ^[1].

Direct measurement of brain or CSF exposure in a living human is the highest grade of evidence for nasal delivery, because it is the evidence that answers whether a spray reaches the brain. What nasal oxytocin trials show covers whether that exposure translates into clinical effects.

How long does a nasal peptide take to reach the brain?

In the human oxytocin study, cerebrospinal fluid levels took up to 75 minutes to reach a significant increase, while plasma peaked at 15 minutes and fell by 75 minutes ^[1]. Those kinetics undercut the "fast bypass" story. The route is diffusion along nerve bundles and perivascular spaces, not an express lane.

Plasma and CSF concentrations were essentially uncorrelated (r < 0.10) ^[1]. Blood levels and brain-fluid levels moved on different timelines and did not track each other, so central exposure cannot be inferred from how much of a molecule shows up in blood.

Any product claim of rapid cognitive or mood effects "straight to the brain" within minutes is unsupported by the kinetics measured in that study.

Do all peptides reach the brain through the nose?

Nose-to-brain delivery is not a universal peptide property: in a mouse study of five radiolabeled incretin-pathway peptides given intranasally, only three achieved widespread brain distribution ^[2]. The three were exenatide, dulaglutide and a designed dual agonist called DA4-JC; the two others did not perform as well ^[2].

The mouse study shows the route is real in an animal model and, just as important, that it is molecule-specific. It is the clearest illustration that "it's a peptide, so it goes nose-to-brain" is not a valid inference ^[2]. Whether a given molecule reaches the brain intranasally depends on its size, charge, stability against nasal enzymes and other specific properties, not on the fact that it was sprayed into a nose.

Do nasal BPC-157, Semax and Selank reach the brain?

None of the studies cited below reports a human cerebrospinal fluid or brain-tissue measurement for BPC-157, Semax or Selank, so whether nasal doses reach the brain in people is unknown. These compounded peptide sprays come up in casual conversation, clinics and podcasts, and the missing data are a real evidence gap, not a minor omission.

Without that data, three explanations for a subjective effect are equally live: central nervous system delivery via the olfactory or trigeminal route, ordinary systemic absorption acting on peripheral or blood-brain-barrier-permeable targets, or a placebo response. None of them has been paired with the randomized, CSF-sampling design used for oxytocin ^[1].

The human outcome data for each peptide are covered separately in Semax's cognitive evidence, Selank's anxiety trials and BPC-157's human studies.

What is still unknown about nose-to-brain peptide delivery?

The open questions sit between the anatomy and the consumer spray bottle:

• Dose fraction. None of the studies cited below supplies a human pharmacokinetic number for what fraction of an ordinary nasal spray dose, delivered the way a person uses one, ends up in brain tissue for the peptides sold in consumer sprays.
• Dose and technique. For BPC-157, Semax, Selank or any similar peptide, the dose, spray technique or formulation needed to reproduce even the modest CSF increases oxytocin showed is unknown.
• Delivery technology. Preclinical and engineering research is trying to close the gap with nanoparticle carriers and better-characterized delivery devices ^[3]⁠^[5]⁠^[6]⁠^[8]. That work is not yet evidence about what a consumer spray does in a person's brain today.